Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397 · see citing works

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208 · see citing works

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103916 · Cited by 673 · see citing works

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Stephenson, K., le Gars, M., Sadoff, J., de Groot, A. M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., et al. (2021) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2021.3645 · Cited by 272 · see citing works

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

Salisch, N. C., Stephenson, K. E., Williams, K. L., Cox, F., van der Fits, L., Heerwegh, D., Truyers, C., Habets, M. N., Kanjilal, D. G., Larocca, R. A., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m20-5306 · Cited by 81 · see citing works

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works

Homologous and Heterologous Covid-19 Booster Vaccinations

Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., Sahly, H. M. E., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116414 · Cited by 629 · see citing works

Humoral and cellular immune memory to four COVID-19 vaccines

Zhang, Z., Mateus, J., Coelho, C. H., Dan, J. M., Moderbacher, C. R., Gálvez, R. I., Côrtes, F. H., Grifoni, A., Tarke, A., Chang, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.05.022 · Cited by 567 · see citing works

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527 · see citing works

Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron

Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M. A., McMahan, K., Sciacca, M., VanWyk, H., Wu, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04465-y · Cited by 451 · see citing works

Covid-19 Vaccines — Immunity, Variants, Boosters

Barouch, D. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2206573 · Cited by 434 · see citing works

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S. M. J., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo2202 · Cited by 401 · see citing works

Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Collier, A.-R. Y., Yu, J., McMahan, K., Liu, J., Chandrashekar, A., Maron, J. S., Atyeo, C. G., Martinez, D. R., Ansel, J. L., Aguayo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2115596 · Cited by 273 · see citing works

Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines

Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 266 · see citing works

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.017 · Cited by 254 · see citing works

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

SADOFF, J. C., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B. G. J., Goepfert, P., Truyers, C., Dromme, I. V., Spiessens, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117608 · Cited by 241 · see citing works

Impact of the delta variant on vaccine efficacy and response strategies

Bian, L., Gao, Q., Gao, F., Wang, Q., He, Q., Wu, X., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1976153 · Cited by 219 · see citing works

T Cell Responses to SARS-CoV-2

Sette, A., Sidney, J., & Crotty, S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-061120 · Cited by 181 · see citing works

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

Bowen, J. E., Addetia, A., Dang, H. V., Stewart, C., Brown, J. T., Sharkey, W. K., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., et al. (2022) · Science · doi:10.1126/science.abq0203 · Cited by 158 · see citing works

Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy

Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 152 · see citing works

Understanding T cell responses to COVID-19 is essential for informing public health strategies

Vardhana, S. A., Baldo, L., Morice, W. G., & Wherry, E. J. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo1303 · Cited by 137 · see citing works

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies

Tada, T., Zhou, H., Samanovic, M. I., Dcosta, B. M., Cornelius, A. R., Herati, R. S., Mulligan, M. J., & Landau, N. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797589 · Cited by 131 · see citing works

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Geers, D., Schmitz, K. S., Garrido, H. M. G., Koopmans, M., Dalm, V. A. S. H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116747 · Cited by 125 · see citing works

Viral vector vaccines

McCann, N. S., O’Connor, D., Lambe, T., & Pollard, A. J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102210 · Cited by 123 · see citing works

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

Keeton, R. S., Richardson, S. I., Moyo-Gwete, T., Hermanus, T., Tincho, M. B., Benede, N., Manamela, N. P., Baguma, R., Makhado, Z., Ngomti, A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.10.003 · Cited by 105 · see citing works

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far

Chavda, V. P., Bezbaruah, R., Deka, K., Nongrang, L., & Kalita, T. (2022) · Vaccines · doi:10.3390/vaccines10111926 · Cited by 103 · see citing works

Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

Firouzabadi, N., Ghasemiyeh, P., Moradishooli, F., & Mohammadi‐Samani, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109968 · Cited by 100 · see citing works

Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms

Atyeo, C. G., Shook, L. L., Brigida, S. M., Guzman, R. M. D., Demidkin, S., Muir, C., Akinwunmi, B. O., Baez, A. M., Sheehan, M. L., McSweeney, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31169-8 · Cited by 99 · see citing works

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Fong, Y., McDermott, A. B., Benkeser, D. C., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Roey, G. A. V., Houchens, C. R., Martins, K. A. O., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01262-1 · Cited by 91 · see citing works

COVID-19 vaccine strategies must focus on severe disease and global equity

McIntyre, P. B., Aggarwal, R., Jani, I. V., Jawad, J. S., Kochhar, S., MacDonald, N. E., Madhi, S. A., Mohsni, E., Mulholland, K., Neuzil, K. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02835-x · Cited by 83 · see citing works

COVID-19 Vaccines: Adenoviral Vectors

Jacob-Dolan, C., & Barouch, D. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-012621-102252 · Cited by 76 · see citing works

The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines

Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Pires, V. C., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Moret, M. A., & Badaró, R. J. D. S. (2022) · Vaccines · doi:10.3390/vaccines10040591 · Cited by 75 · see citing works

Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge

Polinski, J. M., Weckstein, A. R., Batech, M., Kabelac, C. A., Kamath, T. V., Harvey, R. A., Jain, S., Rassen, J. A., Khan, N. S., & Schneeweiß, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2959 · Cited by 76 · see citing works

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71 · see citing works

Defending against SARS-CoV-2: The T cell perspective

Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 64 · see citing works

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Gagné, M., Flynn, B. J., Andrew, S. F., Marquez, J., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01951-5 · Cited by 73 · see citing works

Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months

Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 59 · see citing works

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 55 · see citing works

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

Tan, C. S., Collier, A.-R. Y., Yu, J., Liu, J., Chandrashekar, A., McMahan, K., Jacob-Dolan, C., He, X., Roy, V., Hauser, B. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26335 · Cited by 56 · see citing works

Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors

Waldhorn, I., Holland, R., Goshen‐Lago, T., Shirman, Y., Szwarcwort‐Cohen, M., Benaim, A. R., Shachor‐Meyouhas, Y., Hussein, K., Fahoum, L., Peer, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1072 · Cited by 59 · see citing works

The way of SARS-CoV-2 vaccine development: success and challenges

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53 · see citing works

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Khoo, N. K. H., Lim, J. M. E., Gill, U. S., de Alwis, R., Tan, N., Toh, J. Z. N., Abbott, J. E., Usai, C., Ooi, E. E., Low, J. G. H., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.004 · Cited by 47 · see citing works

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting

SADOFF, J. C., Gars, M. L., Brandenburg, B., Cárdenas, V., Shukarev, G., Vaissière, N., Heerwegh, D., Truyers, C., de Groot, A. M., Jongeneelen, M. A. C., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2022.05.047 · Cited by 47 · see citing works

COVID ‐19 and plasma cells: Is there long‐lived protection?*

Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 44 · see citing works

Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses

Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 45 · see citing works

COVID-19: From emerging variants to vaccination

Senevirathne, T. H., Wekking, D., Swain, J. W. R., Solinas, C., & Silva, P. D. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.005 · Cited by 42 · see citing works

COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Kublin, J. G., & Stephenson, K. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac124 · Cited by 38 · see citing works

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study

Stieh, D. J., Barouch, D. H., Comeaux, C. A., Sarnecki, M., Stephenson, K. E., Walsh, S. R., Sawant, S. S., Heptinstall, J., Tomaras, G. D., Kublin, J. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac445 · Cited by 40 · see citing works

COVID-19 vaccines: Immune correlates and clinical outcomes

Mahrokhian, S. H., Tostanoski, L. H., Vidal, S. J., & Barouch, D. H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2324549 · Cited by 40 · see citing works

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 36 · see citing works

Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review

Gopinath, S., Ishak, A., Dhawan, N., Poudel, S., Shrestha, P. S., Singh, P., Xie, E., Tahir, P., Marzaban, S., Michel, J., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050081 · Cited by 38 · see citing works

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern

Kitchin, D., Richardson, S. I., van der Mescht, M. A., Motlou, T. P., Mzindle, N. B., Moyo-Gwete, T., Makhado, Z., Ayres, F., Manamela, N. P., Spencer, H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100535 · Cited by 35 · see citing works

Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness

Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 37 · see citing works

Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 StudyPreprint

Gray, G., Collie, S., Garrett, N., Goga, A. E., Champion, J., Zylstra, M., Reddy, T., Yende‐Zuma, N., Seocharan, I., Takalani, A., et al. (2021) · medRxiv · doi:10.1101/2021.12.28.21268436 · Cited by 37 · see citing works

Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina

Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M. E., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100123 · Cited by 36 · see citing works

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity

Provine, N. M., & Klenerman, P. (2022) · European Journal of Immunology · doi:10.1002/eji.202250022 · Cited by 37 · see citing works

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S

Barbeau, D. J., Martin, J. M., Carney, E., Dougherty, E., Doyle, J., Dermody, T. S., Hoberman, A., Williams, J. V., Michaels, M. G., Alcorn, J. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00504-x · Cited by 35 · see citing works

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccines

Zhang, G. F., Meng, W., Chen, L., Ding, L., Feng, J., Pérez, J., Ali, A., Sun, S., Liu, Z., Huang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28032 · Cited by 36 · see citing works

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 33 · see citing works

Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021

Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31 · see citing works

Effectiveness of COVID‑19 vaccines and their challenges (Review)

Marfè, G., Perna, S., & Shukla, A. K. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10843 · Cited by 31 · see citing works

Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study

Prather, A. A., Dutcher, E. G., Robinson, J. E., Lin, J., Blackburn, E. H., Hecht, F. M., Mason, A. E., Fromer, E., Merino, B., Frazier, R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33320-x · Cited by 31 · see citing works

Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection

Abebe, E. C., Medhin, M. T. G., T/Mariam, A. B., Dejenie, T. A., Ayele, T. M., Admasu, F. T., Muche, Z. T., & Adela, G. A. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s360103 · Cited by 31 · see citing works

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 32 · see citing works

Post-vaccination T cell immunity to omicron

Jacobsen, H., Jiménez, V. C., Sitaras, I., Bar‐Zeev, N., Čičin‐Šain, L., Higdon, M. M., & Knoll, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944713 · Cited by 30 · see citing works

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Jin, L., Tang, R., Wu, S., Guo, X., Huang, H., Hou, L., Chen, X., Zhu, T., Gou, J.-B., Zhong, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2155251 · Cited by 30 · see citing works

Role of antiviral CD8+ T cell immunity to SARS-CoV-2 infection and vaccination

Karl, V., Hofmann, M., & Thimme, R. (2025) · Journal of Virology · doi:10.1128/jvi.01350-24 · Cited by 34 · see citing works

Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats

Tcheou, J., Raskin, A., Singh, G., Kawabata, H., Bielak, D., Sun, W.-N., González-Domínguez, I., Sather, D., García-Sastre, A., Palese, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791764 · Cited by 27 · see citing works

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant

Risk, M., Shen, C., Hayek, S. S., Holevinski, L., Schiopu, E., Freed, G. L., Akin, C., & Zhao, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac106 · Cited by 28 · see citing works

Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27 · see citing works

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 29 · see citing works

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint

Chen, X., Wang, W., Chen, X., Wu, Q., Sun, R., Ge, S., Zheng, N., Lu, W., Yang, J., Rodewald, L. E., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02249-9 · Cited by 25 · see citing works

Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response

Pušnik, J., König, J., Mai, K., Richter, E., Zorn, J., Proksch, H., Schulte, B., Alter, G., & Streeck, H. (2022) · Journal of Virology · doi:10.1128/jvi.00760-22 · Cited by 27 · see citing works

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG

Dijkman, K., Lindenstrøm, T., Rosenkrands, I., Søe, R., Woodworth, J. S., Arlehamn, C. S. L., & Mortensen, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00666-2 · Cited by 27 · see citing works

HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine

Gutiérrez‐Bautista, J. F., Sampedro, A., Gómez-Vicente, E., Rodríguez‐Granger, J., Reguera, J. A., Cobo, F., Ruiz‐Cabello, F., & López‐Nevot, M. Á. (2022) · Vaccines · doi:10.3390/vaccines10030402 · Cited by 26 · see citing works

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccine

Gars, M. L., Hendriks, J., SADOFF, J. C., Ryser, M., Struyf, F., Douoguih, M., & Schuitemaker, H. (2022) · Immunological Reviews · doi:10.1111/imr.13088 · Cited by 27 · see citing works

Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccinesPreprint

May, D., Rubin, B. E., Dalai, S. C., Patel, K. J., Shafiani, S., Elyanow, R., Noakes, M. T., Snyder, T. M., & Robins, H. S. (2021) · medRxiv · doi:10.1101/2021.12.20.21267877 · Cited by 26 · see citing works

SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes

Kalkeri, R., Cai, Z., Lin, S., Farmer, J., Kuzmichev, Y. V., & Koide, F. (2021) · Microorganisms · doi:10.3390/microorganisms9081744 · Cited by 25 · see citing works

Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling

Ai, J., Guo, J., Zhang, H., Zhang, Y., Yang, H., Lin, K., Song, J., Fu, Z., Fan, M., Zhang, Q., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00480-5 · Cited by 24 · see citing works

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines

Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21 · see citing works

Cellular Immune Response after Vaccination in Patients with Cancer—Review on Past and Present Experiences

Rüthrich, M. M., Giesen, N., Mellinghoff, S. C., Rieger, C. T., & von Lilienfeld‐Toal, M. (2022) · Vaccines · doi:10.3390/vaccines10020182 · Cited by 23 · see citing works

Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population

Sarker, P., Akhtar, E., Kuddusi, R. U., Alam, M. M., Haq, M. A., Hosen, M. B., Chanda, B. C., Haque, F., Alam, M., Razzaque, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10091498 · Cited by 23 · see citing works

Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines

Samanovic, M. I., Oom, A. L., Cornelius, A. R., Gray-Gaillard, S. L., Karmacharya, T., Tuen, M., Wilson, J. P., Tasissa, M., Goins, S., Herati, R. S., et al. (2022) · Vaccines · doi:10.3390/vaccines10122152 · Cited by 21 · see citing works

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024) · Drugs · doi:10.1007/s40265-024-02013-8 · Cited by 23 · see citing works

COVID-19 vaccine boosters: What do we know so far?

Kherabi, Y., Fiolet, T., Rozencwajg, S., Salaün, J., & Peiffer‐Smadja, N. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100959 · Cited by 22 · see citing works

Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients

Hsu, C. M., Weiner, D. E., Aweh, G. N., Manley, H. J., Ladik, V., Frament, J. M., Miskulin, D. C., Argyropoulos, C., Abreo, K. D., Chin, A. I., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.10.002 · Cited by 22 · see citing works

Addressing COVID-19 vaccine hesitancy

Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 22 · see citing works

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans

Cho, A., Muecksch, F., Wang, Z., Tanfous, T. B., DaSilva, J., Raspe, R., Johnson, B. A., Bednarski, E., Ramos, V., Schaefer-Babajew, D. J., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220732 · Cited by 20 · see citing works

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concernPreprint

Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · doi:10.31219/osf.io/z4x7t · Cited by 22 · see citing works

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21 · see citing works

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques

He, X., Aid, M., Chandrashekar, A., Yu, J.-Y., McMahan, K., Wegmann, F., Jacob-Dolan, C., Maron, J. S., Atyeo, C., Wan, H.-H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm4996 · Cited by 20 · see citing works

Delta variant of SARS-CoV-2: characteristics and implications for public health in Colombia

Yomayusa, N., Vega, R., Restrepo, A., Morón, L., Vaca, C., & Oñate, J. (2021) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v70n1.97460 · Cited by 19 · see citing works

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers

Brunner, W. M., Freilich, D., Victory, J. M., Krupa, N. L., Scribani, M., Jenkins, P., Lasher, E. G., Fink, A., Shah, A., Cross, P., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.08.022 · Cited by 19 · see citing works

A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants

Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18 · see citing works

COVID‐19 cooling: Nanostrategies targeting cytokine storm for controlling severe and critical symptoms

Zheng, Y., Li, Y., Mao, L., Wang, R., Jiang, Y., Zhao, M., Lu, J. L., Li, R., Li, X., & Shi, S. (2023) · Medicinal Research Reviews · doi:10.1002/med.21997 · Cited by 17 · see citing works

Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infectionPreprint

Nahass, G. R., Salomon, R. E. A., Blacker, G., Haider, K., Brotherton, R., Teague, K., Yiu, Y. Y., Brewer, R. E., Galloway, S., Hansen, P. S., et al. (2021) · medRxiv · doi:10.1101/2021.08.22.21262168 · Cited by 19 · see citing works

Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis

Meggiolaro, A., Sane Schepisi, M., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2130773 · Cited by 17 · see citing works

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness

Al‐Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M. A., Alshukairi, A. N., Temsah, M.-H. A., Mutair, A. S. A., Rabaan, A. A., Tirupathi, R., & Gautret, P. (2022) · Infection · doi:10.1007/s15010-022-01759-1 · Cited by 17 · see citing works

Effects of Exercise and Physical Activity Levels on Vaccination Efficacy: A Systematic Review and Meta-Analysis

Dinas, P. C., Koutedakis, Y., Ioannou, L. G., Metsios, G. S., & Kitas, G. D. (2022) · Vaccines · doi:10.3390/vaccines10050769 · Cited by 17 · see citing works

T cells in SARS-CoV-2 infection and vaccination

Young, A. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221115011 · Cited by 16 · see citing works

Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

Bonfá, E., da silva, C., Medeiros-Ribeiro, A., Kupa, L. D. V. K., Yuki, E. F. N., Pasoto, S. G., Saad, C., Fusco, S. R. G., Pereira, R., Shinjo, S. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33042-0 · Cited by 16 · see citing works

Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination

Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 16 · see citing works

COVID-19 Associated Cardiovascular Disease—Risks, Prevention and Management: Heart at Risk Due to COVID-19

Kemerley, A., Gupta, A., Thirunavukkarasu, M., Maloney, M., Burgwardt, S., & Maulik, N. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030124 · Cited by 16 · see citing works

Targeting the Complement–Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy

Trivedi, V. S., Magnusen, A. F., Rani, R., Marsili, L., Slavotinek, A. M., Prows, D. R., Hopkin, R. J., McKay, M. A., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214340 · Cited by 15 · see citing works

Induction of humoral and cellular immune responses to COVID‐19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers

Nikolova, M. H., Todorova, Y., Emilova, R., Trifonova, I., Gladnishka, T., Petrova‐Yancheva, N., Chervenyakova, T. P., Dragusheva, E., Popov, G. T., & Christova, I. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27572 · Cited by 13 · see citing works

RCT Abstract - Ad26.COV2.S induces SARS-CoV-2 spike protein-specific cellular immunity and humoral immune responses that cover variants of concern

Gars, M. L., SADOFF, J. C., Shukarev, G., Heerwegh, D., Truyers, C., Scheper, G. C., Hendriks, J., McElrath, M. J., Rosa, S. C. D., Cohen, K. W., et al. (2021) · doi:10.1183/13993003.congress-2021.pa490

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccine

Gars, M. L., Hendriks, J., SADOFF, J. C., Ryser, M., Struyf, F., Douoguih, M., & Schuitemaker, H. (2022) · Immunological Reviews · doi:10.1111/imr.13088 · Cited by 27 · see citing works

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Stephenson, K., le Gars, M., Sadoff, J., de Groot, A. M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., et al. (2021) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2021.3645 · Cited by 272 · see citing works

Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice

Mahrokhian, S. H., Tostanoski, L. H., Jacob-Dolan, C., Zahn, R. C., Wegmann, F., McMahan, K., Yu, J., Gebre, M. S., Bondzie, E. A., Wan, H., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00454-4 · Cited by 10 · see citing works

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Gars, M. L., Stephenson, K. E., Yu, J., Chang, A., Hoof, J. V., Shin, S. A., Chandrashekar, A., Jacob-Dolan, C., Anioke, T., Heerwegh, D., et al. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/phnx-3j92 · Cited by 5 · see citing works